Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVO
Post# of 52
(Total Views: 243)
Posted On: 04/11/2018 7:16:51 PM
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Provides Update on Bio-Cannabis Product Pipeline
- Several proprietary products developed and ready to market in Canada, California and global markets
- Cannabis product sales expected to generate significant revenue
- Pivot’s IP portfolio includes global patents to cement its leading position in the cannabis industry
On April 4, 2018, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) published an update on the advancements of its industry-leading cannabis product pipeline (http://nnw.fm/HHp8E). A newly developed 1% cannabidiol (CBD) oral micelle solution, created in collaboration with the company’s German technology partner, Solmic GmbH, is ready to market. The development of two topical creams using Pivot’s patented formulation and delivery systems is also complete. This formulation will be used to treat a variety of indications, including chemotherapy-induced nausea and vomiting.
Following this development, Pivot anticipates launching several products in Canada when nationwide legalization of cannabis officially begins this summer. The company also expects to begin sales of these products in California during Q3 2018, along with the launch of its proprietary line of ‘Ready-to-Infuse-Cannabis’ (RTIC) natural health products. Sales of bulk powder, stick packs and capsules are expected to generate significant revenue.
Pivot’s current patents provide a critical opportunity for the company to create proprietary products that will be unmatched in quality by other licensed producers and product distributors. Pivot’s intellectual property (IP) portfolio covers several key patents that have demonstrated their ability to deliver pharmaceutical-grade products in clinical trials. The company is ready to manufacture and commercialize its product pipeline in expectation of cannabis legalization in Canada and in regulated international markets.
Pivot’s distinctive business model entails acquiring disruptive drug formulation and delivery technologies, followed by the development of reproducible bio-cannabis products for consumers. The company’s patent-protected products provide significant industry advantages. In accordance with the policy of the World Intellectual Property Organization (WIPO), Pivot’s patents will provide exclusive rights while enabling the company to establish a strong market position and deliver higher returns on investment. They also present opportunities to license or sell inventions and establish a strong position to negotiate with companies that may infringe upon patented rights.
In a news release, Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated, “Canadian Licensed Producers have invested extensively in dried flower and oil production capacity but have not focused on downstream sustainable quality products made from cannabis. Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of bio-cannabis products.”
Pivot Pharmaceuticals is focused on the development and commercialization of cannabinoid-based therapeutic pharmaceutical and nutraceutical products using proprietary drug delivery platform technologies. The research, development and commercialization of products is conducted by the company’s wholly owned subsidiary, Pivot Green Stream Health Solutions Inc. (PGS).
PGS has acquired global rights to BiPhasix™ transdermal drug delivery, Thrudermic transdermal nanotechnology, Solmic oral solubilization and RTIC oil-to-powder technologies. These technologies are used in the development of cannabinoid, CBD and tetrahydrocannabinol (THC) based products. The company’s product development pipeline includes PGS-N001, a candidate for the topical treatment of female sexual dysfunction. Other candidates in the pipeline include PGS-N005 for the treatment of psoriasis and PGS-N007 for cancer supportive care.
Pivot Pharmaceuticals’ development program is well on track toward cementing the company’s position in the cannabis industry. The company’s proprietary pharmaceutical and nutraceutical products are set to establish themselves as leaders in their respective areas of application.
For more information, visit the company’s website at www.PivotPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Several proprietary products developed and ready to market in Canada, California and global markets
- Cannabis product sales expected to generate significant revenue
- Pivot’s IP portfolio includes global patents to cement its leading position in the cannabis industry
On April 4, 2018, Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) published an update on the advancements of its industry-leading cannabis product pipeline (http://nnw.fm/HHp8E). A newly developed 1% cannabidiol (CBD) oral micelle solution, created in collaboration with the company’s German technology partner, Solmic GmbH, is ready to market. The development of two topical creams using Pivot’s patented formulation and delivery systems is also complete. This formulation will be used to treat a variety of indications, including chemotherapy-induced nausea and vomiting.
Following this development, Pivot anticipates launching several products in Canada when nationwide legalization of cannabis officially begins this summer. The company also expects to begin sales of these products in California during Q3 2018, along with the launch of its proprietary line of ‘Ready-to-Infuse-Cannabis’ (RTIC) natural health products. Sales of bulk powder, stick packs and capsules are expected to generate significant revenue.
Pivot’s current patents provide a critical opportunity for the company to create proprietary products that will be unmatched in quality by other licensed producers and product distributors. Pivot’s intellectual property (IP) portfolio covers several key patents that have demonstrated their ability to deliver pharmaceutical-grade products in clinical trials. The company is ready to manufacture and commercialize its product pipeline in expectation of cannabis legalization in Canada and in regulated international markets.
Pivot’s distinctive business model entails acquiring disruptive drug formulation and delivery technologies, followed by the development of reproducible bio-cannabis products for consumers. The company’s patent-protected products provide significant industry advantages. In accordance with the policy of the World Intellectual Property Organization (WIPO), Pivot’s patents will provide exclusive rights while enabling the company to establish a strong market position and deliver higher returns on investment. They also present opportunities to license or sell inventions and establish a strong position to negotiate with companies that may infringe upon patented rights.
In a news release, Dr. Patrick Frankham, CEO of Pivot Pharmaceuticals, stated, “Canadian Licensed Producers have invested extensively in dried flower and oil production capacity but have not focused on downstream sustainable quality products made from cannabis. Consumers deserve and will demand products that work, whereas regulatory authorities will require high quality, reproducible and safe products. Pivot has positioned itself to be the market leader of bio-cannabis products.”
Pivot Pharmaceuticals is focused on the development and commercialization of cannabinoid-based therapeutic pharmaceutical and nutraceutical products using proprietary drug delivery platform technologies. The research, development and commercialization of products is conducted by the company’s wholly owned subsidiary, Pivot Green Stream Health Solutions Inc. (PGS).
PGS has acquired global rights to BiPhasix™ transdermal drug delivery, Thrudermic transdermal nanotechnology, Solmic oral solubilization and RTIC oil-to-powder technologies. These technologies are used in the development of cannabinoid, CBD and tetrahydrocannabinol (THC) based products. The company’s product development pipeline includes PGS-N001, a candidate for the topical treatment of female sexual dysfunction. Other candidates in the pipeline include PGS-N005 for the treatment of psoriasis and PGS-N007 for cancer supportive care.
Pivot Pharmaceuticals’ development program is well on track toward cementing the company’s position in the cannabis industry. The company’s proprietary pharmaceutical and nutraceutical products are set to establish themselves as leaders in their respective areas of application.
For more information, visit the company’s website at www.PivotPharma.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)